Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

Recruiting now

Conditions studied: NTRK Fusion-positive Solid Tumors

In brief

This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.

Key facts

Study ID

NCT07755826

Run by

Bristol-Myers Squibb

People needed

20

Starts

2025-11-20

Expected to finish

2034-04-30

Last updated by the study team

2026-08-10

Who can join

Age: 4 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All pediatric NTRK fusion-positive, advanced or recurrent solid tumors patients (age 4 to < 18) who received Repotrectinib for the approved indications at medical institutions in Japan during enrollment period (for 6 years after approval for this application) will be enrolled in this Post-Marketing Study.

You may not qualify if…

• Participants receiving repotrectinib for an off-label indication

Where it is running

• CMIC Co., Ltd. — Minato-ku, Tokyo, Japan (enrolling)
• EPS Corporation — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.